<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04106349</url>
  </required_header>
  <id_info>
    <org_study_id>A-BE-60000-047</org_study_id>
    <secondary_id>2019-001102-18</secondary_id>
    <nct_id>NCT04106349</nct_id>
  </id_info>
  <brief_title>Observational Real-life Study of Cabozantinib in Advanced Renal Cell Carcinoma (RCC)</brief_title>
  <acronym>REPLICA</acronym>
  <official_title>REPLICA: Real Patient Life Treatment With Cabozantinib in Patients With Advanced or Metastatic RCC: A Descriptive and Prospective Non-Interventional Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ipsen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ipsen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to describe the real-life use of Cabometyx® in Belgium and the
      Netherlands in patients with advanced or metastatic Renal Cell Carcinoma (1st, 2nd and later
      lines of treatment)
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 3, 2020</start_date>
  <completion_date type="Anticipated">May 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 30, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment line</measure>
    <time_frame>Baseline</time_frame>
    <description>Treatment line will be assessed at baseline. It is a percentage of patients receiving cabozantinib as 1st, 2nd or later lines of treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose reductions and reasons</measure>
    <time_frame>From baseline up to 6 to 8 weeks after cabozantinib initiation and within 10 days of cabozantinib stop</time_frame>
    <description>Number of dose reductions and reason</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment interruptions and reason</measure>
    <time_frame>From baseline up to 6 to 8 weeks after cabozantinib initiation and within 10 days of cabozantinib stop</time_frame>
    <description>Number of treatment interruptions and reason</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment discontinuations and reason</measure>
    <time_frame>From baseline up to 6 to 8 weeks after cabozantinib initiation and within 10 days of cabozantinib stop</time_frame>
    <description>Number of patients with permanent discontinuation and reason</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Alternative dose schedule</measure>
    <time_frame>From baseline until the end of study up to 9 months</time_frame>
    <description>Number of patients with schedules other than 1 pill at fixed dose/day for the total treatment period</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean number of any dose modification</measure>
    <time_frame>From baseline up to 6 to 8 weeks after cabozantinib initiation and within 10 days of cabozantinib stop</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Median number of any dose modification</measure>
    <time_frame>From baseline up to 6 to 8 weeks after cabozantinib initiation and within 10 days of cabozantinib stop</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Median time to any first dose modification</measure>
    <time_frame>From baseline up to 6 to 8 weeks after cabozantinib initiation and within 10 days of cabozantinib stop</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Median time to end of treatment</measure>
    <time_frame>From baseline until the end of study up to 9 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of treatment exposure</measure>
    <time_frame>From baseline until the end of study up to 9 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose prescribed at initiation</measure>
    <time_frame>Baseline</time_frame>
    <description>Number of patients with dose of 60 mg/day, 40 mg/day or 20 mg/day at baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Average daily dose</measure>
    <time_frame>From baseline until the end of study up to 9 months</time_frame>
    <description>Estimation of average daily dose received by subject during the treatment exposure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life score</measure>
    <time_frame>From baseline up to 6 to 8 weeks after cabozantinib initiation and within 10 days of cabozantinib stop</time_frame>
    <description>Changes in quality of life data by comparing changes in scores on Using the National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Kidney Symptom Index-19 (NFKSI-19). It describes the severity, interference, and frequency rates.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>From baseline until the end of study up to 9 months</time_frame>
    <description>Radiological progression using RECIST 1.1 or investigator assessed or according to local standard of care or death; PFS evaluated at least every 12 weeks under treatment with cabozantinib</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>From baseline until the end of study up to 9 months</time_frame>
    <description>Percent of patients with partial and complete response during the treatment with cabozantinib</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate</measure>
    <time_frame>From baseline until the end of study up to 9 months</time_frame>
    <description>Percent of patients with stable disease, partial and complete response during the treatment with cabozantinib</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Advanced or Metastatic Renal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>1st line</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>2nd line</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>later lines</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        advanced or metastatic renal cell carcinoma
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or females aged 18 years and older

          -  Patients scheduled to receive Cabometyx® for advanced or metastatic renal cell
             carcinoma

          -  Decision to treat patients with Cabometyx® has to be taken prior to and independent
             from participation in the clinical study

          -  Provision of written informed consent

        Exclusion Criteria:

          -  Participation in another clinical study at the same time

          -  Previous participation in this clinical study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ipsen Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Ipsen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ipsen Recruitment Enquiries</last_name>
    <email>clinical.trials@ipsen.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Onze-Lieve-vrouw Ziekenhuis Aalst</name>
      <address>
        <city>Aalst</city>
        <zip>9300</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vivalia Hôpital d'Arlon</name>
      <address>
        <city>Arlon</city>
        <zip>6700</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>AZ Sint-Jan Brugge</name>
      <address>
        <city>Brugge</city>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ziekenhuis Oost-Limburg Genk</name>
      <address>
        <city>Genk</city>
        <zip>3600</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHR Citadelle Liège</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Liège / Sart-Tilman</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Ambroise-Paré Mons</name>
      <address>
        <city>Mons</city>
        <zip>7000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>AZ Turnhout</name>
      <address>
        <city>Turnhout</city>
        <zip>2300</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UCL Namur - site Godinne</name>
      <address>
        <city>Yvoir</city>
        <zip>5530</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>September 25, 2019</study_first_submitted>
  <study_first_submitted_qc>September 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 27, 2019</study_first_posted>
  <last_update_submitted>June 25, 2020</last_update_submitted>
  <last_update_submitted_qc>June 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

